Immediate and long term effects of weight reduction in obese people with asthma: randomised controlled study

Brita Stenius-Aarniala, Tuija Poussa, Johanna Kvarnström, Eeva-Liisa Grönlund, Mikko Ylikahri and Pertti Mustajoki

BMJ 2000;320:827-832
doi:10.1136/bmj.320.7238.827

Updated information and services can be found at: http://bmj.com/cgi/content/full/320/7238/827

These include:

Data supplement
"Flow chart and table"
http://bmj.com/cgi/content/full/320/7238/827/DC1

References
This article cites 12 articles, 7 of which can be accessed free at:
http://bmj.com/cgi/content/full/320/7238/827#BIBL

45 online articles that cite this article can be accessed at:
http://bmj.com/cgi/content/full/320/7238/827#otherarticles

Rapid responses
3 rapid responses have been posted to this article, which you can access for free at:
http://bmj.com/cgi/content/full/320/7238/827#responses

You can respond to this article at:
http://bmj.com/cgi/eletter-submit/320/7238/827

Email alerting service
Receive free email alerts when new articles cite this article - sign up in the box at the top left of the article

Topic collections Articles on similar topics can be found in the following collections

Other nutrition and metabolism (1280 articles)
Asthma (1223 articles)

Correction
A correction has been published for this article. The contents of the correction have been appended to the original article in this reprint. The correction is available online at:
http://bmj.com/cgi/content/full/320/7240/984

Notes

To order reprints follow the "Request Permissions" link in the navigation box

To subscribe to BMJ go to:
http://resources.bmj.com/bmj/subscribers
Immediate and long term effects of weight reduction in obese people with asthma: randomised controlled study

Brita Stenius-Aarniala, Tuija Poussa, Johanna Kvarnström, Eeva-Liisa Grönlund, Mikko Ylikahri, Pertti Mustajoki

Abstract

Objective To investigate the influence of weight reduction on obese patients with asthma.

Design Open study, two randomised parallel groups.

Setting Private outpatients centre, Helsinki, Finland.

Participants Two groups of 19 obese patients with asthma (body mass index (kg/m²) 30 to 42) recruited through newspaper advertisements.

Intervention Supervised weight reduction programme including 8 week very low energy diet.

Main outcome measures Body weight, morning peak expiratory flow (PEF), forced vital capacity (FVC), forced expiratory volume in one second (FEV₁); and also asthma symptoms, number of acute episodes, courses of oral steroids, health status (quality of life).

Results At the end of the weight reducing programme, the participants in the treatment group had lost a mean of 14.5% of their pretreatment weight, the controls 0.3%. The corresponding figures after one year were 11.3% and a weight gain of 2.2%. After the 8 week diet period the difference in changes in percentage of predicted FEV₁ from baseline in the treatment and control groups was 7.2% (95% confidence interval 1.9% to 12.5%), P = 0.009. The corresponding difference in the changes in FVC was 8.6% (4.8% to 12.5%, P < 0.0001). After one year the differences in the changes in the two groups were still significant: 7.6% for FEV₁ (1.5% to 13.8%, P = 0.02) and 7.6% for FVC (3.5% to 11.8%, P = 0.001). By the end of the weight reduction programme, reduction in dyspnoea was 13 mm (on a visual analogue scale 0 mm to 100 mm) in the treatment group and 1 mm in the control group (P = 0.02). The reduction of rescue medication was 1.2 and 0.1 doses respectively (P = 0.03). After one year the differences in the changes between the two groups were −12 for symptom scores (range −1 to −22, P = 0.04) and −10 for total scores (−18 to −1, P = 0.02). The median number of exacerbations in the treatment group was 1 (0–4) and in the controls 4 (0–7), P = 0.001.

Conclusion Weight reduction in obese patients with asthma improves lung function, symptoms, morbidity, and health status.
acceptable. In six cases medication had to be intensified. During the baseline period and the study period, medication was changed only during episodes of exacerbation of the asthma. One participant with an uncertain history of allergy to peas and beans was excluded because a test dose of the dietary preparation caused immediate allergic symptoms.

After a two to three week run-in period with lung function measurements and laboratory tests, 38 participants fulfilled the inclusion criteria (see BMJ’s website for flow chart showing exclusions). After two weeks of baseline measurements, the participants were randomised to a treatment group (19) and a control group (19). Randomisation was by “shuffling cards,” with the help of someone not involved in the study. Clinical data are presented in table A on the BMJ’s website.

The treatment group took part in a weight reduction programme that included 12 group sessions and lasted 14 weeks, including eight weeks—“the dieting period”—in which participants took a very low energy dietary preparation (Nutrilite (Nynomed Pharma, Oslo)). The daily dose gave 1760 kJ of energy and contained daily allowances of all essential nutrients, as described elsewhere. The principles and behaviour methods of this weight reduction programme are also described elsewhere. The control group had sessions at the same intervals as the treatment group; each session lasted half an hour, during which time themes chosen by the group were discussed freely. These themes were discussed with the treatment group at later sessions; by the end of the first year each group had had the same amount of education about asthma and allergy.

All participants received normal medical care throughout the study. Using a mini-Wright peak flow meter and taking the best of three consecutive blows into account, the participants measured their daily morning and evening prebronchodilator and postbronchodilator peak expiratory flow (PEF) during the dieting period, and thereafter during the two weeks before each group meeting. The mean of the previous two weeks’ premedication PEF values served for calculation. Forced vital capacity (FVC) and forced expiratory volume in one second (FEV1) were measured by means of a mini-Wright spirometer at baseline, at the end of the dieting period, at the end of the 14 week weight reduction programme, at six months, and at one year. During the peak flow follow up periods, asthma symptoms were recorded on a 100 mm visual analogue scale (where 0 mm represented “best possible” and 100 mm “worst possible”) and rescue medication was recorded as the number of daily doses of an inhaled bronchodilator. Serum cortisol and diurnal urine cortisol excretion concentrations and blood and urine concentrations of sodium, potassium, calcium, magnesium, triglycerides, and cholesterol were measured at baseline, at the end of the dieting period, and after 14 weeks. Health status was investigated four times during the first year, using the St George’s respiratory questionnaire, which is divided into three parts: symptoms (distress caused by specific respiratory symptoms); activity (physical activities that cause or are limited by breathlessness); and impact (social and psychological effects of the disease). The total score is derived from all items and is expressed as a percentage of the maximum possible. A decrease in the score indicated an improvement in health status. A translated Finnish version of this questionnaire has been used previously. The data from the questionnaires on health status were compiled with the help of software designed by P W Jones (St George's Hospital, London). All 38 participants were followed for one year. Two participants found the consistency or taste of the dietary preparation intolerable but followed a low energy diet; one participant started smoking during the study. These three participants were retained in the study.

Statistical analysis

Determination of sample size was based on the change in daily PEF (l/min). It was originally assumed that PEF would increase by 50 l/min in the treatment group and by 20 l/min in the control group. It was assumed that a difference in change of 30 litres or more between the groups would be clinically significant. To demonstrate this, with a standard deviation of 25 l/min, a power of 80%, and a power of 90%, 15 participants per group were required to complete the study. However, owing to chance, the baseline difference between the groups was 36 litres (treatment group, 423 litres; control group, 387 litres)—that is, greater than the expected treatment difference. Also owing to chance, the proportion of men was higher in the treatment group, which can explain the baseline differences expressed in litres. To control for the possible differences in sex, age, and height distributions, the analysis was based on percentage of predicted values. The groups were similar for these baseline values and for all other participant characteristics except rhinitis (see table A on website). The mean numbers of PEF recordings were 13.9 (range 12-14), 13.6 (7-14), 13.7 (11-14), 13.5 (5-14) and 13.7 (8-14) for the five two-week periods. The mean of all usable PEF recordings was used as the mean value for the period.

The data were analysed by means of StatView 512 + TM (Brainpower) for Apple Macintosh and SPSS 9.0 for Windows. The changes from baseline were calculated for lung function, and the t test for independent samples was used to compare the treatment group with the control group. The 95% confidence intervals were calculated for change within a treatment group and for difference between groups. Changes in symptoms and use of rescue sympathomimetics were analysed by the non-parametric Mann-Whitney U test. Changes in health status subscores and in laboratory variables were analysed by the t test for independent samples. The χ2 test was used for binary variables.

Secondary analyses

Secondary analyses were performed to control for the multiplicity of data. Analysis of variance for repeated measurements was performed to compare the changes from baseline in the lung function variables in the two study groups. We studied (a) the difference between study groups; (b) the time effect—that is, change during the follow up period; and (c) interaction between group and time effect. Repeated measurements of symptoms (dyspnoea, cough) and use of sympathomimetics during the follow up were reduced to the mean of all measurements, and the overall changes from baseline were calculated. The Mann-Whitney U test was used to compare the treatment group with controls.
Mean change in percentage of predicted morning peak expiratory flow (PEF), forced expiratory volume in one second (FEV₁), and forced vital capacity (FVC) from baseline to end of very low energy diet (dieting period), end of weight reduction programme, and follow up visits at 6 months and 1 year. Values in parentheses are 95% confidence intervals

<table>
<thead>
<tr>
<th></th>
<th>Change in treatment group</th>
<th>Change in control group</th>
<th>Difference between treatment and control</th>
<th>P value*</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>PEF (% of predicted):</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>End of dieting period</td>
<td>6.1 (2.4 to 9.7)</td>
<td>1.3 (-2.5 to 5.1)</td>
<td>4.8 (-0.3 to 9.8)</td>
<td>0.06</td>
</tr>
<tr>
<td>End of weight reduction programme</td>
<td>4.5 (-0.9 to 9.8)</td>
<td>-0.3 (-4.8 to 4.1)</td>
<td>4.8 (-1.9 to 11.4)</td>
<td>0.16</td>
</tr>
<tr>
<td>6 months</td>
<td>4.1 (-1.5 to 9.8)</td>
<td>-0.6 (-5.5 to 4.3)</td>
<td>4.7 (-2.5 to 11.8)</td>
<td>0.19</td>
</tr>
<tr>
<td>1 year</td>
<td>5.6 (-0.2 to 11.4)</td>
<td>-0.6 (-5.8 to 4.7)</td>
<td>6.2 (-1.4 to 13.7)</td>
<td>0.11</td>
</tr>
<tr>
<td><strong>FEV₁ (% of predicted):</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>End of dieting period</td>
<td>7.3 (3.5 to 11.1)</td>
<td>0.1 (-3.8 to 4.0)</td>
<td>7.2 (1.8 to 12.5)</td>
<td>0.009</td>
</tr>
<tr>
<td>End of weight reduction programme</td>
<td>5.3 (2.2 to 8.4)</td>
<td>-1.5 (-5.1 to 2.2)</td>
<td>6.7 (2.1 to 11.4)</td>
<td>0.006</td>
</tr>
<tr>
<td>6 months</td>
<td>6.5 (3.3 to 10.7)</td>
<td>-1.9 (-4.7 to 0.8)</td>
<td>8.4 (3.7 to 13.2)</td>
<td>0.001</td>
</tr>
<tr>
<td>1 year</td>
<td>4.9 (-0.5 to 10.3)</td>
<td>-2.7 (-5.8 to 0.5)</td>
<td>7.6 (1.5 to 13.8)</td>
<td>0.02</td>
</tr>
<tr>
<td><strong>FVC (% of predicted):</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>End of dieting period</td>
<td>3.4 (0.8 to 6.1)</td>
<td>-5.2 (-8.2 to -2.2)</td>
<td>8.6 (4.8 to 12.4)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>End of weight reduction programme</td>
<td>1.9 (-0.7 to 4.4)</td>
<td>-5.6 (-9.8 to -1.5)</td>
<td>7.4 (2.8 to 12.1)</td>
<td>0.002</td>
</tr>
<tr>
<td>6 months</td>
<td>1.7 (-1.3 to 4.7)</td>
<td>-6.0 (-8.2 to -3.7)</td>
<td>7.6 (4.1 to 11.2)</td>
<td>0.0001</td>
</tr>
<tr>
<td>1 year</td>
<td>2.0 (-1.4 to 5.4)</td>
<td>-5.6 (-8.2 to -3.1)</td>
<td>7.6 (3.5 to 11.8)</td>
<td>0.001</td>
</tr>
</tbody>
</table>

*Difference between changes from baseline shows significant difference between groups (see table for P values)†Based on results from 18 patients.

**Results**

**Weight reduction**

Mean weight reduction in the treatment group was 14.2 kg (range 7.7-22.1 kg), or 14.5% of pretreatment weight at the end of the weight reduction programme. At this point, nine participants had lost ≥15% of their weight, eight participants 10.0-14.9%, and two participants 5.0-9.9%. After one year the mean weight reduction was 11.1 kg (1.1-22.5 kg), or 11.3%. In the control group the corresponding changes in weight were small—a mean weight loss of 0.5 kg at the end of the programme and a mean gain of 2.3 kg (2.2%) after one year.

**Lung function tests**

The table and figure 1 show the mean changes in lung function variables. The increase in PEF (% of predicted) at the end of the dieting period in the treatment group compared with the controls was not significant (P = 0.06, table). The FEV₁ (% of predicted) increased significantly more in the treatment group than in the controls. Even after one year, the difference was 7.6% (95% confidence interval 1.5% to 13.8%; P = 0.02). The FVC (% of predicted) improved in the treatment group and decreased in the controls. After one year the difference was 7.6% (5.5% to 11.8%; P = 0.001). Analysis of variance for repeated measurements showed a significant difference between groups for the FEV₁ (7.9% (3.4% to 12.4%); P = 0.001) and for the FVC (7.9% (4.4% to 11.4%); P = 0.0001). For the PEF the difference was 5.1% (-1.2% to 11.4%; P = 0.11). The period effects and interaction effects were not significant.

**Symptoms**

Changes in cough, dyspnoea and use of rescue medication are shown in figure 2. By the end of the weight reduction programme the median reduction in dyspnoea in the treatment group was 13 mm on the visual analogue scale (1 mm in the controls). The daily use of rescue sympathomimetics decreased by 1.2 doses (median) in the treatment group (0.1 doses in the controls). For dyspnoea the P values for the difference in scores between groups were P = 0.09 at the end of the dieting period, P = 0.02 at the end of the weight reduction programme, P = 0.09 at 6 months, and P = 0.12 after one year. Corresponding P values for
rescue medication were \( P = 0.02, P = 0.03, P = 0.10, \) and \( P = 0.08 \). The changes in cough were non-significant (fig 2).

In the secondary analyses, the overall median change in dyspnoea was \(-13\) mm in the treatment group (\(-2\) mm in the controls) \((P = 0.03)\). The overall change in cough was \(-1.8\) mm in the treatment group (\(-1.3\) mm in the controls) \((P = 0.07)\). Overall reduction in rescue medication was 0.5 doses and zero doses respectively \((P = 0.002)\). During the year of follow up, 18 participants in the control group and 16 in the treatment group experienced at least one exacerbation of their asthma. The median number of exacerbations was 1 (range 0-7) in the control group and 1 (0-4) in the treatment group \((P = 0.001)\). Thirteen controls and 10 participants in the treatment group needed a course of oral steroids \((P = 0.07)\). The median number of courses of oral steroids was two (0-3) in the control group and one (0-4) in the treatment group.

**Health status**

For the treatment group, health status improved with respect to all three subscales when compared with controls (fig 3). After one year the difference between groups was \(-12\) (95% confidence interval \(-22\) to \(-1\); \(P = 0.04\)) for symptom scores; \(-9\) (\(-19\) to \(-1\); \(P = 0.07\)) for activity scores; \(-8\) (\(-17\) to \(-2\); \(P = 0.10\)) for impact scores; and \(-10\) (\(-18\) to \(-1\); \(P = 0.02\)) for total scores.

**Laboratory values**

During the weight reduction programme, no significant changes occurred in serum or urine cortisol concentration or in the urinary excretion concentrations of sodium, calcium, magnesium, or phosphorus. At the end of the dieting period, the mean urinary excretion concentration of sodium decreased significantly in the treatment group compared with the control group \((112 \ (SD \ 54) \ mmol/l \ v 124 \ (42) \ mmol/l; \ P = 0.01)\). The corresponding figures for magnesium were 2.8 \((1.1)\) to 1.5 \((1.1)\) and 3.1 \((1.1)\) to 2.6 \((0.9)\) \((P = 0.004)\). The serum concentrations for sodium, potassium, calcium, and magnesium fell within normal limits, never differing between groups throughout the study.
Discussion

This trial showed that in obese people with asthma losing weight can improve asthma in terms of lung function, symptoms, and health status. Several possible explanations exist for this improvement in asthma during and after weight reduction. In asthma, airway obstruction causes early airway closure during expiration. This feature is accentuated by overweight, especially when patients are lying down. Weight reduction reduces closing capacity—that is, dependent airways close later in expiration—which tends to increase the forced expiratory volume in one second and the forced vital capacity. In asthmatic people, this may also lead to a reduction in clinical symptoms. Weight reduction also reduces the exercise load, which may alleviate asthma symptoms during exercise. Gastrointestinal reflux may worsen asthma symptoms, and reduction of fat around the abdomen may reduce reflux, thus alleviating symptoms. The psychological benefit of having lost weight may also alleviate symptoms.

Although general symptoms and lung function improved in the treatment group, use of rescue medication remained unchanged. This may reflect the fact that, whereas the overall clinical picture of the asthma was improved by the weight reduction, airway hyperreactivity persisted. No investigations into hyperreactivity during weight reduction have so far been reported. The decrease in urinary concentrations of sodium and magnesium during the weight reduction programme probably did not influence asthma symptoms. Low sodium intake may alleviate asthma, but other evidence shows that reduced magnesium intake may worsen it.

The weight reduction regimen was well tolerated by the participants and caused no problems with medication and no exacerbations of the asthma. Nine months after the weight reduction programme began, all 19 participants in the treatment group had lost more than 5%, and 17 more than 10%, of their original weight. This shows satisfactory weight loss and maintenance. The fact that no participants dropped out and asthma symptoms improved suggests that a weight reduction programme based on a very low energy dietary preparation is acceptable for patients with asthma. Allergy to any of the ingredients in the preparation, however, should be taken into consideration.

This weight reduction programme was suitable for groups, and its 12 sessions were fewer than in most current programmes. A trained nurse for group supervision currently costs about £1050 ($1680) in Finland; the cost per patient would therefore depend on the size of the group. In the clinical setting the additional costs are low because no routine laboratory tests are required, and patients usually purchase their own dietary preparations. We believe therefore that this weight reduction regimen is suitable for clinical work and that the benefits associated with weight reduction in obese patients with asthma can be achieved at reasonable cost.

The nature of the intervention was such that the trial could not be blinded. After randomisation the members of the control group might have felt disappointed, which could have influenced their evaluation of symptoms and health status. Within the trial regimen, however, the control group received similar attention as often as the treatment group; in addition, controls were offered a similar weight reduction programme to start immediately after the trial.

We thank specialist nurses Anne Nurrinkumpu, Päivi Helin, and Marjana Körpinen for keeping the study together and the records in order, for help with arranging the programme for the control group; and for superintending the weight reducing regimen; Professor P W Jones for supplying the software application and instructions for analysing the health status database; Ms Teri Kovanen for creating the database; Ms Heli Tofferi-Saarinen and Ms Sirpa Hultanen for computer assistance and finalising the manuscript; Dr Carol Norris for language editing; and the participants for their patience in making this study possible.

Contributors: BS-A had the original idea for the study, designed the protocol, participated in the active investigation, and wrote the paper. PM supervised the weight reduction programme, revised the manuscript, and wrote the sections on weight loss. TP was responsible for the data analysis, methodology and wrote the sections on statistical methods. JK compiled the health status data. E-LG and MY participated in the planning of the study, the practical work, and the creation of the database. BS-A is the guarantor for the paper.

Funding: The Finnish Culture Foundation, the Association of the Pulmonary Disabled, and the Wilhelm and Else Stockmann Foundation. Nycomed Pharma supplied the dietary preparation (Nutrilett) free of charge.

Competing interests: None declared.

Trainee satisfaction before and after the Calman reforms of specialist training: questionnaire survey

Elisabeth Paice, Maryanne Aitken, George Cowan, Shelley Heard

Abstract

Objectives To evaluate the impact of the Calman reforms of higher specialist training on trainee satisfaction.

Design Questionnaire surveys using portable electronic survey units, two years apart.

Setting Postgraduate, teaching, district general, and community NHS trusts in North Thames. North Thames deanery includes London north of the Thames, Essex, and Hertfordshire.

Participants Trainees in all grades and all specialties: 3078 took part in the first survey and 3517 in the second survey.

Main outcome measures Trainees’ satisfaction with training in their current post, including educational objectives, training agreements, induction, consultant feedback, hands on experience acquired, use of log books, consultant supervision, and overall satisfaction with the post.

Results In the second survey respondents were more likely to have discussed educational objectives with their consultant, used a log book, and had useful feedback from their consultant. They were more likely to give high ratings to induction, consultant supervision, and hands on experience acquired in the post. Each of these elements was associated with increased satisfaction with the post overall. Improvements were most noticeable at the level of specialist registrar, but changes in the same direction were also seen in more junior grades.

Conclusions After the reforms of specialist training, trainees in all grades reported greater satisfaction with their current posts. The changes required extra training time and effort from consultants.

Introduction

In 1992 Kenneth Calman, then chief medical officer, set up a working group to bring the British system of specialist training into line with the requirements of the European medical directives. The resulting report recommended combining the registrar and senior registrar grades into a unified specialist registrar grade and defining the curriculum and minimum training period for each specialty, the successful completion of which would lead to admission to the specialist registrar. Features of the new system were set out in A Guide to Specialist Registrar Training and included educational objective setting, training agreements, and induction at the start of each placement; rotational placements designed to offer specified experience; and regular feedback on progress from the supervising consultant. The reforms were to be cost neutral, and no additional resources were made available to NHS trusts for their implementation. Transition to the new system began in December 1995 and was completed in April 1997.

The new arrangements placed more emphasis on structured teaching and supervised learning and less on experiential apprenticeship. Although the reforms received a cautious welcome, there were anxieties about the impact of shortening the training time on trainees’ experience especially since junior doctors’ hours were being reduced. It was expected that the reforms would lead fewer trainees and more consultants. Consultants feared they would be expected to take on extra responsibility for out of hours emergency work, including resident on-call, although this was denied by senior doctors involved in planning the reforms.

The implementation of the reforms seemed likely to create a major new training workload for consultants. At the same time they were losing control over appointment of their own junior colleagues, who were to be appointed to regional programmes and allocated to posts by a regional committee. It was not clear whether the reforms could be delivered without additional resources, how motivated the consultants would be to implement change, whether higher specialist trainees would consider their training improved, or what the impact would be on the training of more junior grades.

To evaluate the impact of the reforms on specialist registrars (including old style registrars and senior registrars) and any knock-on effects on more junior grades (preregistration house officers and senior house officers), we planned two surveys of trainees in all grades and all specialties in our region: one during transition to the new system and one two years later.

Participants and methods

Surveys

The first survey took place during transition in November and December 1996, with postal questionnaires to non-responders in January 1997. The second survey took place 18 months after transition was
What is already known on this topic

In many areas there is widespread concern about the possible association between illegal drug use and violence

Previous research carried out in the United States has identified a close association between the carrying of weapons and use of illegal drugs by young people

Little comparative information is available on the possible relation between weapons and drugs in young people in the United Kingdom

What this study adds

Weapon carrying is comparatively widespread among young people in Scotland

Over a third of males surveyed and nearly a tenth of females had carried a weapon, and such weapon carrying was closely associated with the use of illegal drugs

A national educational campaign is needed, stressing the risks and dangers of weapon carrying among young people

Discussion

These data on weapon carrying and illegal drug use in adolescents are based on self report and so may contain both underreporting and overreporting. It is important to bear in mind that weapon carrying refers to ever having carried a weapon. With these limitations in mind the data must give cause for concern.

The west of Scotland has had an association with weapon carrying and gang fights for many years, immortalised in the “no mean city” account of life in Glasgow. On the basis of the data presented here, the culture of weapon carrying among young people seems to be continuing although it is not confined to any one city. It is far from clear why a substantial proportion of young people in Scotland feel the need to carry a weapon and this needs further investigation. Whatever the reasons, having a weapon potentially increases the risk of harm. Research in the United States has shown an association between involvement in violence and the use of illegal drugs. It is possible that a proportion of young people in Scotland who use illegal drugs will become involved in violence, and some of these may carry weapons.

Agencies working with young people need to better understand why some young people feel the need to carry weapons and to discourage this behaviour. Where such weapon carrying relates to the young person feeling vulnerable, it may need to be tackled in the context of broader approaches, for example, in relation to bullying. One report found that the carrying of weapons at school was associated with fights, having had goods stolen or damaged, and threats of injury with a weapon while at school.

Organisers of events where young people congregate clearly need to be aware that some young people may be carrying a weapon and to take steps to reduce this likelihood. National information and educational campaigns into the dangers of weapon carrying are needed, targeted at young people and parents. Finally, although the UK home secretary has advised that adults should be more prepared to intervene when young people misbehave, we suggest the need for caution as some young people may be carrying an offensive weapon.

We thank all the participating schools, particularly the young people surveyed.

Contributors: NMK initiated the study and wrote the first draft of the paper. JN carried out the statistical analyses and redrafted the paper in the light of comments from referees. Dr Marina Barnard and Dr Alasdair Forsyth developed the core instrument used in the school surveys and were involved in the data collection and coding. Mrs Lesley Reid supervised the part time interviewing staff associated with the research. Professor Neil McKeganey will act as guarantor for the paper.

Funding: Scottish Executive Department of Health and the Lanarkshire Drug Action Team. The views expressed in this paper are those of the authors and should not be attributed to either funding body.

Competing interests: None declared.


(Accepted 13 January 2000)

Corrections and clarifications

ABC of arterial and venous disease: Acute limb ischaemia

In the section entitled “Saddle embolus” (p 765) in this article by Ken Callum and Andrew Bradbury (18 March, pp 764-7), an editing slip led to a presence rather than an absence of femoral pulses. The first sentence should have begun: “Patients with acute embolic occlusion of the aortic bifurcation have no femoral pulses.”

Immediate and long term effects of weight reduction in obese people with asthma: randomised controlled study

In this paper by Brita Stenius-Aarniala et al (25 March, pp 827-32) we inadvertently failed to remove a reference to error bars from the caption to figure 1. The graphs in the figure are correct; there should be no error bars. Moreover, Perti Mustajoki, one of the authors, is a consultant in endocrinology (not pulmonary medicine).

Systematic reviews and meta-analyses on treatment of asthma: critical evaluation

In this paper by Alejandro R Jadad (25 February, pp 537-40) the first author’s name in reference 27 slipped through wrongly spelt; the correct spelling is Hammarquist.